Literature DB >> 3512339

Effects of obesity, hyperinsulinemia, and glucose intolerance on insulin action in adipose tissue of sixty-year-old men.

J Bolinder, H Lithell, E Skarfors, P Arner.   

Abstract

The relative effects of obesity alone, and in combination with fasting hyperinsulinemia and glucose intolerance, on the peripheral action of insulin in adipose tissue were investigated in twenty-four 60-yr-old men, who had been followed for 10 yr. They were divided into four groups of six subjects each on the basis of the following criteria: (1) normal body weight, normal fasting insulin level, and normal glucose tolerance; (2) moderate obesity, normal fasting insulin level, and normal glucose tolerance; (3) moderate obesity, fasting hyperinsulinemia, and normal glucose tolerance; and (4) moderate obesity, fasting hyperinsulinemia, and newly developed, moderate, untreated fasting hyperglycemia and/or glucose intolerance (i.e., mild type II diabetes mellitus). Specific adipocyte insulin binding and the effects of the hormone on adipose tissue lipolysis and glucose oxidation were determined. Insulin receptor binding per cell and per cell surface area were similar in all four groups. Regarding antilipolysis, the insulin sensitivity was the same in all groups and the maximum effect was significantly increased in the three obese groups, as compared with the normal-weight control group. In groups 1-3, insulin stimulated adipose tissue glucose oxidation in a dose-dependent way, and the sensitivity and responsiveness to insulin were comparable. In contrast, in the obese glucose-intolerant subjects (4) there was no significant effect of insulin on glucose oxidation when the hormone was added in increasing concentrations of less than or equal to 35 nmol/L. The basal glucose oxidation was similar in all four study groups. The in vivo insulin tolerance was gradually reduced in groups 2-4, as compared with the normal-weight control group.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3512339     DOI: 10.2337/diab.35.3.282

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  8 in total

1.  Defective insulin receptor tyrosine kinase in human skeletal muscle in obesity and type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  P Arner; T Pollare; H Lithell; J N Livingston
Journal:  Diabetologia       Date:  1987-06       Impact factor: 10.122

2.  Strong association between mitochondrial DNA copy number and lipogenesis in human white adipose tissue.

Authors:  M Kaaman; L M Sparks; V van Harmelen; S R Smith; E Sjölin; I Dahlman; P Arner
Journal:  Diabetologia       Date:  2007-09-19       Impact factor: 10.122

Review 3.  Potential of surgery for curing type 2 diabetes mellitus.

Authors:  Francesco Rubino; Michel Gagner
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

Review 4.  Regulation of lipolysis in adipocytes.

Authors:  Robin E Duncan; Maryam Ahmadian; Kathy Jaworski; Eszter Sarkadi-Nagy; Hei Sook Sul
Journal:  Annu Rev Nutr       Date:  2007       Impact factor: 11.848

5.  On the interplay between insulin secretion and sensitivity as determinants of glucose tolerance.

Authors:  L Lind; H Lithell; T Pollare; S Ljunghall
Journal:  Acta Diabetol       Date:  1994-04       Impact factor: 4.280

6.  Different aetiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects.

Authors:  P Arner; T Pollare; H Lithell
Journal:  Diabetologia       Date:  1991-07       Impact factor: 10.122

7.  Characterisation of insulin-like growth factor I receptor in skeletal muscles of normal and insulin resistant subjects.

Authors:  N Livingston; T Pollare; H Lithell; P Arner
Journal:  Diabetologia       Date:  1988-12       Impact factor: 10.122

8.  Allograft inflammatory factor 1 (AIF-1) is a new human adipokine involved in adipose inflammation in obese women.

Authors:  Silvia Lorente-Cebrián; Pauline Decaunes; Elisabeth Dungner; Anne Bouloumié; Peter Arner; Ingrid Dahlman
Journal:  BMC Endocr Disord       Date:  2013-11-25       Impact factor: 2.763

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.